Add the result to your basket Make a suggestion Refine your search Apply to external sources
Extend search on down-posting(s)
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention / AS Dela Pena in Journal of gastrointestinal surgery, 10(2006)4 ([04/01/2006])
[article] Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention [printed text] / AS Dela Pena, Author ; W. Asperger, Author ; F. Köckerling, Author ; R. Raz, Author ; R. Kafka, Author ; B. Warren, Author ; M. Shivaprakash, Author ; France Vrijens , Author ; H. Giezek, Author ; M.J. DiNubile, Author ; C.Y. Chan, Author . - 2006 . - 567-74.
Languages : English (eng)
in Journal of gastrointestinal surgery > 10(2006)4 [04/01/2006] . - 567-74
W 1 Serials. Periodicals
Abdomen ; Abscess ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Alanine Transaminase ; Anti-Bacterial Agents ; Bacterial Infections ; Bacteroides Infections ; beta-Lactams ; Escherichia coli Infections ; Female ; Gastrointestinal Diseases ; Humans ; Journal Article ; Male ; Middle Aged ; Peer Review ; Penicillanic Acid ; Peritonitis ; Piperacillin ; Prospective Studies ; Treatment outcome ; United States
Abstract: Complicated intra-abdominal infections usually mandate prompt surgical intervention supplemented by appropriate antimicrobial therapy. The aim of this study was to demonstrate that ertapenem was not inferior to piperacillin-tazobactam for the treatment of community-acquired intra-abdominal infections. A randomized open-label active-comparator clinical trial was conducted at 48 medical centers on four continents from December 2001 to February 2003. Adult patients with intra-abdominal infections requiring surgery were randomized to receive either ertapenem 1 g daily or piperacillin/tazobactam 13.5 g daily in 3-4 divided doses. The primary analysis of efficacy was the clinical response rate in clinically and microbiologically evaluable patients at the test-of-cure assessment 2 weeks after completion of therapy. All treated patients were included in the safety analysis. Patient demographics, disease characteristics, and treatment duration in both treatment groups were generally similar. The most commonly isolated pathogens at baseline were E coli (greater than 50% of cases in each group) and B fragilis ( approximately 9%). Favorable clinical response rates were 107/119 (90%) for ertapenem recipients and 107/114 (94%) for piperacillin/tazobactam recipients. The frequencies of drug-related adverse events, most commonly diarrhea and elevated serum alanine aminotransferase levels, were similar in both treatment groups. Six of 180 ertapenem recipients (3%) and two of 190 piperacillin/tazobactam recipients (1%) had serious drug-related adverse experiences. In this study, ertapenem and piperacillin/tazobactam were comparably safe and effective treatments for adult patients with complicated intra-abdominal infections. Link for e-copy: http://www.springerlink.com.vdicp.health.fgov.be:8080/content/9077246g0q14079g/f [...] Format of e-copy: VDIC IP recognition Record link: [article]EORTC-GCG process quality indicators for ovarian cancer surgery / Leen Verleye in European journal of cancer, 45(2009)04 ([03/01/2009])
[article] EORTC-GCG process quality indicators for ovarian cancer surgery [printed text] / Leen Verleye, Author ; Petronella B. Ottevanger, Author ; Winette Van der Graaf, Author ; Nick S. Reed, Author ; Ignace Vergote, Author . - 2009 . - 517-526.
Languages : English (eng)
in European journal of cancer > 45(2009)04 [03/01/2009] . - 517-526
W 1 Serials. Periodicals
Abdomen ; Female ; Humans ; Hysterectomy ; Journal Article ; Lymph Node Excision ; Lymphatic Metastasis ; Neoplasm Invasiveness ; Neoplasm Staging ; Ovarian Neoplasms ; Ovariectomy ; Peer Review ; Practice Guideline [Publication type] ; Prognosis ; Quality Indicators, Health Care ; Time Factors
Surgery is the mainstay of staging and treatment of ovarian cancer. Optimal quality of ovarian cancer surgery implies complete staging and removal of all macroscopic tumour with minimal harm to the patient in order to ensure best patient outcome. However, variation in the quality of ovarian cancer surgery is apparent. In order to assess and improve the quality of care, quality indicators can be used.
To identify candidate quality indicators, a literature search was performed using relevant MESH terms. These were assessed for validity, feasibility and measurability.
Five quality indicators for staging of presumed early-stage ovarian cancer and six for primary debulking surgery for advanced disease are proposed.
The defined quality indicators can be used to monitor and improve the quality of surgery for ovarian cancer.
Link for e-copy: http://www.sciencedirect.com.vdicp.health.fgov.be:8080/science/journal/09598049 Format of e-copy: VDIC IP recognition Record link: [article]